glp 1 drugs and cancer Could GLP-1 Reduce Obesity-Related Cancers in the Future? Dr. - The GLP-1 cancer

doi: 10.1038/jcbfm.2011.51 83 DarsaliaVLarssonMNathansonDKleinTNystrmTPatroneC

Trial data showed that Saxenda , in combination with a reduced-calorie diet and increased physical activity, resulted in significantly greater weight loss in some patients than reduced-calorie diet and physical activity alone

Nausea and vomiting are less frequent in patients receiving EX-LAR than in patients taking EX (114)

mSphere 5 (1), e00585-19

doi: 10.1056/NEJMoa1008862 3 HolmanRRPaulSKBethelMAMatthewsDRNeilHA

Clinical trials of GLP-1RAs have primarily focused on patients with obesity or overweight, yet the effectiveness in the cardiovascular protection appears independent of baseline BMI range (265)